Immuta
Immuta is a data governance company whose platform automates data access control, policy enforcement, and compliance for organizations.
Secondary Market Price
How Immuta Measures Up
To help you manage your Immuta equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series E
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Immuta's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Immuta Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Immuta's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Immuta is a data security company that develops a platform for data access control and provisioning. The company's software automates policy enforcement, access requests, and auditing to provide governed data access for both human users and artificial intelligence applications. It integrates with cloud data platforms including Snowflake, Databricks, and Google BigQuery, and serves organizations in sectors such as finance, healthcare, and government. Founded in 2015 by Matthew Carroll, Steve Touw, and Mike Schiller, the company is headquartered in Boston, Massachusetts, with additional offices in the US and Europe. Immuta has raised multiple funding rounds, including a Series E in June 2023, and reached a valuation of $1 billion in June 2022.
The company is focused on supporting the growth of AI by providing scalable and automated data governance. Recent developments include a case study on how AstraZeneca used Immuta's platform to build an internal data marketplace for its research and development data. Immuta also received a testimonial from the CEO of LMI on the platform's ability to create and audit data access rules. In public commentary, Immuta's CEO Matthew Carroll has highlighted the growing importance of data provisioning as a core dependency for successful AI initiatives. The company has also announced product updates, such as its Simplified Connections Experience, designed to make it easier for organizations to manage their data environments.
- NightDragon
- Snowflake Ventures
- Dell Technologies Capital
- DFJ Growth
- Intel Capital
- Ten Eleven Ventures
- March Capital
- Greenspring Associates
- NGP Capital
- Wipro Ventures
- Citi Ventures
- Okta Ventures
- StepStone Group
- IAG
- Co-Founder, Matthew Carroll
- Co-Founder, Steven Touw
- Co-Founder, Michael Schiller
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Immuta worth joining?
Deciding if a startup is the right fit depends on your personal career and financial goals. Tools like Prospect can help you make an informed choice by providing data-driven projections to compare potential equity outcomes at different companies.
What should I do with my Immuta stock?
The optimal strategy for your Immuta stock depends on your financial situation, risk tolerance, and long-term goals. A platform like Prospect can help you build a personalized plan by modeling different scenarios and creating tax-optimized strategies for your shares.
Can you sell Immuta stock?
As Immuta is a private company, its stock isn't traded on public exchanges, but you can often sell shares during secondary market transactions or company-approved tender offers. Navigating these liquidity events can be complex, but equity management tools can help you determine which shares are most tax-optimal to sell.
How can I find the value of my Immuta stock?
Valuing private stock involves looking at the company's 409A valuation, recent funding rounds, and any secondary market data. To get a more comprehensive picture, services like Prospect use machine learning models to forecast the future value of private shares based on proprietary data.
What is Immuta's equity worth?
The ultimate worth of your Immuta equity is its after-tax value in your pocket, which goes beyond the company's current valuation. Prospect can help you calculate your potential net outcome by modeling exercise costs, tax liabilities, and future growth scenarios.
What is Immuta's stock ticker symbol?
Because it is a privately held company, Immuta does not have a stock ticker symbol and its shares are not available on a public stock exchange. A ticker symbol is only assigned to a company after it completes an Initial Public Offering (IPO).
Can I buy or sell Immuta stock?
Selling private Immuta stock is generally possible during specific liquidity events like tender offers, while buying is typically limited to employees exercising their stock options. Platforms like Prospect offer tools to help you decide when to exercise options and how to sell shares in a tax-efficient manner.
What is the criteria to buy or invest in Immuta stock?
Investing in a private company like Immuta is typically restricted to employees receiving equity compensation or accredited investors participating in funding rounds or secondary sales. These investment opportunities are generally not available to the public until the company completes an IPO.
